"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil"

Clin Genitourin Cancer. 2023 Apr;21(2):e58-e69. doi: 10.1016/j.clgc.2022.09.005. Epub 2022 Sep 10.

Abstract

Introduction: Non-metastatic, castration-resistant prostate cancer (nmCRPC) is an important clinical stage of prostate cancer, prior to morbidity and mortality from clinical metastases. In particular, the introduction of novel androgen-receptor signaling inhibitors (ARSi) has changed the therapeutic landscape in nmCRPC. Given recent developments in this field, we update our recommendations for the management of nmCRPC.

Methods: A panel of 51 invited medical oncologists and urologists convened in May of 2021 with the aim of discussing and providing recommendations regarding the most relevant issues concerning staging methods, antineoplastic therapy, osteoclast-targeted therapy, and patient follow-up in nmCRPC. Panel members considered the available evidence and their practical experience to address the 73 multiple-choice questions presented.

Results: Key recommendations and findings include the reliance on prostate-specific antigen doubling time for treatment decisions, the absence of a clear preference between conventional and novel (i.e., positron-emission tomography-based) imaging techniques, the increasing role of ARSis in various settings, the general view that ARSis have similar efficacy. Panelists highlighted the slight preference for darolutamide, when safety is of greater concern, and a continued need to develop high-level evidence to guide the intensity of follow-up in this subset of prostate cancer.

Discussion: Despite the limitations associated with a consensus panel, the topics addressed are relevant in current practice, and the recommendations can help practicing clinicians to provide state-of-the-art treatment to patients with nmCRPC in Brazil and other countries with similar healthcare settings.

Keywords: Androgen-receptor signalling inhibitors; Castration-resistant prostate cancer; Non-metastatic; Practice guidelines; Prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androgen Receptor Antagonists / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Brazil
  • Consensus
  • Humans
  • Male
  • Neoplasm Staging
  • Osteoclasts
  • Prostatic Neoplasms, Castration-Resistant* / diagnosis
  • Prostatic Neoplasms, Castration-Resistant* / therapy

Substances

  • Antineoplastic Agents
  • darolutamide
  • Androgen Receptor Antagonists